Letter by Groothof et al Regarding Article, "Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial"

被引：0
|
作者：
Groothof, Dion [1 ]
Post, Adrian [1 ]
Bakker, Stephan J. L. [1 ]
机构：
[1] Univ Med Ctr Groningen, Div Nephrol, Dept Internal Med, Groningen, Netherlands
来源：
CIRCULATION | 2022年 / 146卷 / 02期
关键词：
D O I：
10.1161/CIRCULATIONAHA.122.060263
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E5 / E6
页数：2
相关论文
共 50 条
  • [21] Association of British Clinical Diabetologists (ABCD) position statement on the use of sodium-glucose cotransporter-2 inhibitors in type 1 diabetes (updated 2019)
    Dashora, Umesh
    Patel, Dipesh C.
    Gregory, Robert
    Winocour, Peter
    Dhatariya, Ketan
    Nagi, Dinesh
    BRITISH JOURNAL OF DIABETES, 2019, 19 (01): : 66 - 72
  • [22] Letter by Taegtmeyer and Karlstaedt Regarding Article, "Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)"
    Taegtmeyer, Heinrich
    Karlstaedt, Anja
    CIRCULATION, 2018, 137 (09) : 986 - 987
  • [23] Factors associated with the uric acid-lowering effects of sodium-glucose cotransporter-2 inhibition in patients with type 2 diabetes: Insights from the randomized PROTECT trial
    Saito, Yuichi
    Tanaka, Atsushi
    Imai, Takumi
    Miura, Shin-Ichiro
    Ajioka, Masayoshi
    Kodama, Kazuhisa
    Kobayashi, Yoshio
    Node, Koichi
    DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 1110 - 1113
  • [24] Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study
    Jang, Jaehyuk
    Park, Soyoon
    Kim, Soohyun
    Kim, Sung-Hwan
    Oh, Yong-Seog
    Sa, Young Kyoung
    Hwang, Youmi
    Jang, Sung-Won
    Ihm, Sang-Hyun
    Choi, Young
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (03) : 320 - 329
  • [25] Renal, cardiovascular, and safety outcomes of adding sodium-glucose cotransporter-2 inhibitors to insulin therapy in patients with type-2 diabetes: a meta-analysis
    Zhang, Qian
    Zhang, Qingqing
    Yang, Liu
    Yang, Shufang
    Lu, Yu
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2024, 56 (02) : 557 - 570
  • [26] Clinical and biochemical outcomes of Sodium-Glucose CoTransporter-2 (SGLT2) Inhibitors in Type-2 Diabetes Mellitus Patients as a fourth oral anti diabetic medicine
    Saleem, Muhammad
    Khan, Sajjad Ali
    Suchal, Zafar Aleem
    Ram, Nanik
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2022, 38 (05) : 1255 - 1259
  • [27] Sodium-Glucose Cotransporter-2 Inhibitors versus Glucagon-Like Peptide 1 Receptor Agonists Effects on Kidney and Clinical Outcomes in Veterans with Type 2 Diabetes
    Morello, Candis M.
    Awdishu, Linda
    Lam, Stepfanie
    Heman, Amy
    Bounthavong, Mark
    KIDNEY360, 2024, 5 (11): : 1633 - 1643
  • [28] Letter by Matthews et al Regarding Article, "Class Effect for Sodium Glucose-Cotransporter-2 Inhibitors in Cardiovascular Outcomes: Implications for the Cardiovascular Disease Specialist"
    Matthews, David R.
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    CIRCULATION, 2018, 138 (06) : 660 - 661
  • [29] Sodium-glucose cotransporter-2 inhibitors and kidney outcomes in real-world type 2 diabetes populations: A systematic review and meta-analysis of observational studies
    Forbes, Anna K.
    Suckling, Rebecca J.
    Hinton, William
    Feher, Michael D.
    Banerjee, Debasish
    Cole, Nicholas I.
    de Lusignan, Simon
    Swift, Pauline A.
    DIABETES OBESITY & METABOLISM, 2023, 25 (08): : 2310 - 2330
  • [30] Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
    Wu, Jason H. Y.
    Foote, Celine
    Blomster, Juuso
    Toyama, Tadashi
    Perkovic, Vlado
    Sundstrom, Johan
    Neal, Bruce
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (05): : 411 - 419
12345